Key result
Only ~11% of STEMI patients meet ESC primary prevention criteria at presentation, though older age predicts compliance.
Why the study?
Cardiovascular disease risk assessment identifies individuals who could benefit from primary prevention pharmacotherapy, but baseline risk and guideline-directed risk-factor control among patients presenting with STEMI needed evaluation.
Observational (n=202)
No
Answers are grounded in this paper and cite their sources.
Most patients presenting with STEMI have high baseline cardiovascular risk but fail to meet ESC guideline targets for primary prevention prior to their event.
Introduction and objectives Cardiovascular disease (CVD) risk assessment allows the identification of individuals at risk that could benefit from pharmacological intervention in primary prevention. The aim of this study is to evaluate baseline CVD risk of patients admitted with ST-elevation myocardial infarction (STEMI), assess STEP 1 and STEP 2 accomplishment and determine predictors of appropriate CVD control. Methods A retrospective, observational study was conducted on 202 patients diagnosed with STEMI between January 1st, 2022 and March 31, 2023. Risk stratification was performed using the ESC 2021 Guidelines on cardiovascular disease prevention in clinical practice, and compliance with STEP 1 and STEP 2 (target LDL-C and systolic blood pressure control) was analysed. Lifestyle changes were not addressed in this study. Results Patients presented a mean age of 61.8 years (±11.4). CV risk stratification identified 56.4% (n= 114) patients with high and 40.1% (n= 81) with very high risk. Concerning CV risk control, at the time of the event, only 10.9% of patients (n=22) met STEP 1 criteria, and just 2 patients achieved STEP 2. Age was significantly associated with the accomplishment of STEP 1 (OR: 1.069; p= 0.001). Statin use and recent analytical study at the general practitioner showed no significant association with STEP 1 compliance. Conclusion Most patients who develop STEMI failed to meet ESC 2021 Guidelines on cardiovascular disease prevention, despite their high baseline CVD risk. Age emerged as a predictor of compliance with CV prevention strategies, emphasizing the need for targeted interventions among the younger population.
No takes yet. Share an insight, caveat, or question.
Ferreira et al. (2026) conducted an observational in ST-elevation myocardial infarction (STEMI) (n=202). Primary cardiovascular disease prevention (STEP 1 and STEP 2 compliance) was evaluated on Compliance with STEP 1 criteria (target LDL-C and systolic blood pressure control) (OR 1.069, p=0.001). Among STEMI patients, only 10.9% met ESC 2021 STEP 1 primary prevention criteria at the time of their event, with older age predicting compliance.
Synapse has enriched 10 related papers. Consider them for comparative context: